ArticleThe American journal of pathology2001
Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 122 citations in OpenAlex.
- Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Haematologica · 2015Trial
- Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy.Journal of clinical medicine · 2026Review
- Kidney Transplantation in Patients with Multiple Myeloma: Current Evidence, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Diagnosing Polyomavirus Nephropathy Without a Biopsy: Validation of the Urinary Polyomavirus-Haufen Test in a Proof-of-Concept Study Including Uromodulin Knockout Mice.The Journal of infectious diseases · 2024Article
- Uromodulin Regulates Murine Aquaporin-2 Activity via Thick Ascending Limb-Collecting Duct Cross-Talk during Water Deprivation.International journal of molecular sciences · 2022Article
- Review
- Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.International journal of nephrology and renovascular disease · 2022Review
- Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apoptosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein.Iranian journal of public health · 2020Article
- Article
- The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.Auto- immunity highlights · 2020Review
- Renal Expression of Light Chain Binding Proteins.Frontiers in medicine · 2020Article
- Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis.The Journal of clinical investigation · 2019Article
- Myeloma light chain cast nephropathy, a review.Journal of nephrology · 2019Review
- Treatment of multiple myeloma with renal involvement: the nephrologist's view.Clinical kidney journal · 2018Article
- Animal models of monoclonal immunoglobulin-related renal diseases.Nature reviews. Nephrology · 2018Review
- Tamm-Horsfall Protein is a Potent Immunomodulatory Molecule and a Disease Biomarker in the Urinary System.Molecules (Basel, Switzerland) · 2018Review
- The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Review
- Uromodulin: from physiology to rare and complex kidney disorders.Nature reviews. Nephrology · 2017Review
- Pathogenesis of renal failure in multiple myeloma: any role of contrast media?BioMed research international · 2014Review
- Uromodulin upregulates TRPV5 by impairing caveolin-mediated endocytosis.Kidney international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cast nephropathy, or myeloma kidney, is a potentially reversible cause of chronic renal failure. In this condition, filtered light chains bind to a common site on Tamm-Horsfall protein (THP), which is produced by cells of the thick ascending limb of the loop of HENLE: Subsequent aggregation of these proteins produces casts that obstruct tubule fluid flow and results in renal failure. In the present study, we used the yeast two-hybrid system to determine the site of interaction of light chains with THP. The third complementarity-determining region (CDR3) of both kappa and lambda light chains interacted with THP. These findings were confirmed in a series of competition studies using a synthetic peptide that corresponded to the CDR3 region and purified THP and light chains. Variations in the CDR3 sequence of the light chain affected binding. Thus, the current studies increase our understanding of the process of cast formation and provide an opportunity to develop strategies that may inhibit this interaction and prevent the clinical manifestations of myeloma kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.